drugset
drugset / Trial / NCT01279954

Abatacept in the Treatment of Uveitis

NCT01279954 ↗

Phase 2 Completed 10 enrolled Oregon Health and Science University Bristol-Myers Squibb · collab
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to assess the safety and efficacy of abatacept in the treatment of uveitis.

Timeline

Start
2012-01
Primary completion
2017-06
Completion
2017-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Abatacept Other / unclassified 5 mg/kg Intravenous
Subject Abatacept Other / unclassified 10 mg/kg Intravenous

Indications

uveitis